<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">39334235</PMID><DateCompleted><Year>2024</Year><Month>09</Month><Day>28</Day></DateCompleted><DateRevised><Year>2024</Year><Month>09</Month><Day>30</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1750-1172</ISSN><JournalIssue CitedMedium="Internet"><Volume>19</Volume><Issue>1</Issue><PubDate><Year>2024</Year><Month>Sep</Month><Day>27</Day></PubDate></JournalIssue><Title>Orphanet journal of rare diseases</Title><ISOAbbreviation>Orphanet J Rare Dis</ISOAbbreviation></Journal><ArticleTitle>COVID-19 risk factors and outcomes in individuals with stiff person syndrome spectrum disorders before and after omicron.</ArticleTitle><Pagination><StartPage>356</StartPage><MedlinePgn>356</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">356</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1186/s13023-024-03357-w</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Stiff person syndrome spectrum disorders (SPSD) are rare, disabling disorders of the nervous system that are associated with risk factors for Coronavirus disease 2019 (COVID-19). However, limited data exist on the overall impact of COVID-19 on SPSD.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Patients with SPSD and COVID-19 who are followed at Johns Hopkins SPS Center were included. Demographics and SPSD characteristics along with COVID-19-specific data were recorded.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Thirty-five cases of SPSD with COVID-19 cases were reported during the study time period. Mean age of the cohort was 56 (SD ± 10) and most were female (66.7%). Eighty percent of the COVID-19 cases were confirmed with testing, and the rest were highly suggestive of COVID-19. COVID-19 comorbidities among patients were hypertension (n = 6), diabetes (n = 6), obesity (n = 5), and cardiovascular disease (n = 4). The majority of participants were on immune therapies and/or benzodiazepines. Out of the cases reported, only 2 required hospitalization, both of whom had diabetes, and one was on immunosuppressive therapy. The majority of cases were post-full-vaccination cases. Fever was the most common COVID-19-associated symptom. Transient neurological symptoms were also reported.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Risk factors for developing severe COVID-19 in SPSD appear to be the same as historical data in the general population. Importantly, COVID-19 did not appear to be associated with worsening SPSD post-COVID-19. Vaccination may have played a role in preventing severe cases of COVID-19.</AbstractText><CopyrightInformation>© 2024. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Afshar</LastName><ForeName>Hanyeh</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Johns Hopkins University School of Medicine, Baltimore, MD, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Simpson</LastName><ForeName>Alexandra</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Johns Hopkins University School of Medicine, Baltimore, MD, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Taylor</LastName><ForeName>Elena</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Johns Hopkins University School of Medicine, Baltimore, MD, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Miles</LastName><ForeName>Ashley</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Johns Hopkins University School of Medicine, Baltimore, MD, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Herbert R</ForeName><Initials>HR</Initials><AffiliationInfo><Affiliation>Johns Hopkins University School of Medicine, Baltimore, MD, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Newsome</LastName><ForeName>Scott D</ForeName><Initials>SD</Initials><Identifier Source="ORCID">0000-0002-5284-4681</Identifier><AffiliationInfo><Affiliation>Johns Hopkins University School of Medicine, Baltimore, MD, USA. snewsom2@jhmi.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>09</Month><Day>27</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Orphanet J Rare Dis</MedlineTA><NlmUniqueID>101266602</NlmUniqueID><ISSNLinking>1750-1172</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016750" MajorTopicYN="Y">Stiff-Person Syndrome</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="Y">SARS-CoV-2</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015897" MajorTopicYN="N">Comorbidity</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">Neurology</Keyword><Keyword MajorTopicYN="N">SPSD</Keyword><Keyword MajorTopicYN="N">Stiff person syndrome</Keyword><Keyword MajorTopicYN="N">Vaccination</Keyword></KeywordList><CoiStatement>The authors declare that they have no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>1</Month><Day>3</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>9</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>9</Month><Day>28</Day><Hour>22</Hour><Minute>45</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>9</Month><Day>28</Day><Hour>22</Hour><Minute>44</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>9</Month><Day>28</Day><Hour>0</Hour><Minute>23</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>9</Month><Day>27</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39334235</ArticleId><ArticleId IdType="pmc">PMC11428925</ArticleId><ArticleId IdType="doi">10.1186/s13023-024-03357-w</ArticleId><ArticleId IdType="pii">10.1186/s13023-024-03357-w</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Levy LM, Dalakas MC, Floeter MK. The stiff-person syndrome: An autoimmune disorder affecting neurotransmission of γ-aminobutyric acid. Ann Intern Med. 1999;131(7):522. 10.7326/0003-4819-131-7-199910050-00008.</Citation><ArticleIdList><ArticleId IdType="pubmed">10507962</ArticleId></ArticleIdList></Reference><Reference><Citation>Dalakas MC, Fujii M, Li M, McElroy B. The clinical spectrum of anti-GAD antibody-positive patients with stiff-person syndrome. Neurology. 2000;55(10):1531–5. 10.1212/wnl.55.10.1531.</Citation><ArticleIdList><ArticleId IdType="pubmed">11094109</ArticleId></ArticleIdList></Reference><Reference><Citation>Callender LA, Curran M, Bates SM, Mairesse M, Weigandt J, Betts CJ. The impact of pre-existing comorbidities and therapeutic interventions on COVID-19. Front Immunol. 2020;11:1991. 10.3389/fimmu.2020.01991.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7437504</ArticleId><ArticleId IdType="pubmed">32903476</ArticleId></ArticleIdList></Reference><Reference><Citation>Pérez CA, Zhang G-Q, Li X, et al. Covid-19 severity and outcome in multiple sclerosis: results of a national, registry-based, matched Cohort Study. Multiple Scler Relat Disord. 2021;55: 103217. 10.1016/j.msard.2021.103217.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8366056</ArticleId><ArticleId IdType="pubmed">34418735</ArticleId></ArticleIdList></Reference><Reference><Citation>Salter A, Fox RJ, Newsome SD, et al. Outcomes and risk factors associated with SARS-COV-2 infection in a North American registry of patients with multiple sclerosis. JAMA Neurol. 2021;78(6):699. 10.1001/jamaneurol.2021.0688.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7980147</ArticleId><ArticleId IdType="pubmed">33739362</ArticleId></ArticleIdList></Reference><Reference><Citation>Ortiz JF, Ghani MR, Morillo Cox Á, et al. Stiff-person syndrome: a treatment update and new directions. Cureus. 2020. 10.7759/cureus.11995.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7793517</ArticleId><ArticleId IdType="pubmed">33437550</ArticleId></ArticleIdList></Reference><Reference><Citation>Simpson-Yap S, De Brouwer E, Kalincik T, et al. Associations of DMT therapies with COVID-19 severity in multiple sclerosis. Neurology. 2021. 10.1101/2021.02.08.21251316.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8601210</ArticleId><ArticleId IdType="pubmed">34610987</ArticleId></ArticleIdList></Reference><Reference><Citation>Boekel L, Wolbink GJ. Rituximab during the COVID-19 pandemic: time to discuss treatment options with patients. Lancet Rheumatol. 2022;4(3):e154–5. 10.1016/s2665-9913(21)00418-5.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8700274</ArticleId><ArticleId IdType="pubmed">34977601</ArticleId></ArticleIdList></Reference><Reference><Citation>Park HY, Kwon J, An SK, Park E-C. A nationwide cohort study of the association of benzodiazepines with SARS-COV-2 infection and clinical outcomes. Sci Rep. 2022;12(1):15947. 10.1038/s41598-022-20335-z.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9509375</ArticleId><ArticleId IdType="pubmed">36153398</ArticleId></ArticleIdList></Reference><Reference><Citation>Nyberg T, Ferguson NM, Nash SG, et al. Comparative analysis of the risks of hospitalisation and death associated with SARS-COV-2 omicron (b.1.1.529) and delta (b.1.617.2) variants in England: a cohort study. Lancet. 2022;399(10332):1303–12. 10.1016/s0140-6736(22)00462-7.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8926413</ArticleId><ArticleId IdType="pubmed">35305296</ArticleId></ArticleIdList></Reference><Reference><Citation>Accorsi EK, Britton A, Fleming-Dutra KE, et al. Association between 3 doses of mrna COVID-19 vaccine and symptomatic infection caused by the SARS-COV-2 omicron and delta variants. JAMA. 2022;327(7):639. 10.1001/jama.2022.0470.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8848203</ArticleId><ArticleId IdType="pubmed">35060999</ArticleId></ArticleIdList></Reference><Reference><Citation>Vaughan A. Omicron emerges. New Sci. 2021;252(3363):7. 10.1016/s0262-4079(21)02140-0.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8639363</ArticleId><ArticleId IdType="pubmed">34876769</ArticleId></ArticleIdList></Reference><Reference><Citation>SARS-COV-2 B.1.1.529 (omicron) variant-United States, December 1–8, 2021. Centers for Disease Control and Prevention. December 16, 2021. https://www.cdc.gov/mmwr/volumes/70/wr/mm7050e1.htm. Accessed 1 July 2024.</Citation></Reference><Reference><Citation>FDA approves first oral antiviral for treatment of covid-19 in adults. U.S. Food and Drug Administration. https://www.fda.gov/news-events/press-announcements/fda-approves-first-oral-antiviral-treatment-covid-19-adults. Accessed 2 July 2023.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle>